| |
Bruker Corporation today announced a strategic collaboration with Translucence Biosystems, Inc., a leading provider of tissue-clearing solutions, to expand its workflow for cleared tissue imaging. Through the combined use of Translucence’s Universal Tissue Clearing Kit alongside Bruker’s light-sheet microscopy and data processing platforms, researchers can move from sample preparation to high-resolution, analysis-ready 3D datasets with greater efficiency and ease.
The Universal Tissue Clearing Kit is designed to support user-defined antibodies and requires no specialized equipment. Its accessibility and flexibility enable researchers to implement standardized clearing workflows in typical laboratory environments while reducing variability.
Bruker’s MuVi SPIM and LCS SPIM light-sheet microscopes are optimized for 3D imaging of cleared samples, from intricate tissue structures to entire organisms. These systems are supported by a software suite that offers high-speed registration and fusion of large, multi-view datasets. Bruker also provides scalable data management, visualization, and processing with its Acquifer HIVE platform.
Together, these complementary technologies support a streamlined workflow for cleared tissue imaging, enabling researchers to align sample preparation, imaging, and data processing steps more effectively. This approach facilitates consistent generation of high-quality 3D datasets while improving usability, reproducibility, and scalability across a range of biological research applications.
“We developed our Universal Tissue Clearing Kit to make high-quality 3D histology more consistent and broadly accessible across different sample types,” said Damian Wheeler, Ph.D., Co-Founder and CEO of Translucence Biosystems. “By combining this foundation with Bruker’s imaging and data capabilities, we can extend the impact of our approach and provide researchers with a more powerful and cohesive solution for whole-organ analysis.”
“Today’s researchers are increasingly looking for complete workflows,” added Xiaomei Li, Ph.D., Senior Vice President and General Manager of Bruker Fluorescence Microscopy. “This collaboration simplifies 3D imaging workflow, improves reproducibility, and enables researchers to generate meaningful biological insights more efficiently. We believe this partnership will help accelerate discoveries across both basic research and emerging translational applications.”
About Bruker Corporation
Bruker (bruker.com) is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
|
steve.hopkins[.]bruker.com 
